Wegovy and Zepbound are part of a wave of obesity medications known as GLP-1 receptor agonists that have soared in popularity ...

The market reaction came as Trump signed a wide-ranging executive order aimed at slashing prescription drug prices in the US.

CVS Caremark decided to stop offering Zepbound in favor of Wegovy for weight loss. It’s the latest example of limits imposed ...

In addition to eliciting greater weight loss than Novo Nordisk’s Wegovy, Eli Lilly’s Zepbound does not come at the expense of ...

Following the sell-off, Lilly trades at a forward price-to-earnings (P/E) of 37 times 2025 analyst estimates, with a price-to ...

Eli Lilly's stock suffered a nearly 12% loss in markets Thursday despite strong earnings, in what analysts say is an ...

Eli Lilly won’t lose its grip on the weight loss market despite recent investor concerns. Meanwhile, Zocdoc releases an ...

CompanyOverview|NYSE:LLY] The world’s largest pharmaceutical stock, Eli Lilly and Company (NYSE: LLY), recently had its worst ...

Risinger also lowered Eli Lilly's price target from $989 to $944 on the formulary news, calling it a negative in a note Thursday. The deal with CVS is the latest this week as Novo Nordisk pushes ...

Eli Lilly said on Sunday its drug Zepbound was superior to Novo Nordisk's Wegovy across five weight-loss targets such as ...

Looking for undervalued stocks? Check out three top undervalued stocks to buy now in May, 2025 to boost your portfolio.

Kicking Lilly while it was down, CVS Health CVS announced a key partnership with Lilly’s arch-rival, Novo Nordisk A/S NVO, that sent shares even lower. The two companies are angling against ...